GlassScriptPhysician profile
Chris Z Thomas
NPI 1922539824
$1,058.46
in general payments reported to CMS, 2019-2025
11 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $95.00 · 2023: $400 · 2024: $83.50 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $211.37 | 2023 | |
| Boston Scientific Corporation | $161.05 | 2023-2025 | Avvigo Guidance System, Opticross, Synergy |
| Axonics, INC. | $145.50 | 2023 | Axonics |
| United Therapeutics Corporation | $119.17 | 2023-2025 | Tyvaso |
| Genmab U.S., INC. | $113.40 | 2025 | Epkinly |
| Genzyme Corporation | $108.17 | 2021 | |
| Seagen INC. | $95.00 | 2022 | |
| Melinta Therapeutics, LLC | $33.53 | 2025 | Rezzayo |
| Bayer Healthcare Pharmaceuticals INC. | $28.39 | 2025 | |
| Cleerly, INC. | $27.60 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Scpharmaceuticals INC. | $15.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.